Journal of the National Comprehensive Cancer Network · 2017 · 151 citations · 52 references
MedicineHematologyOncologyHematologic OncologyHematopathologyNeoplasiaBone Marrow EvaluationBone Marrow PathologyHematologic MalignanciesHematologic Malignancy TherapyHematopoietic NeoplasmsMyeloproliferative NeoplasmsHematopoietic DisordersMyeloid NeoplasmsMyeloproliferative Neoplasm AssessmentMyeloproliferative Neoplasm TherapyMyeloproliferative Neoplasm TreatmentSpecial Considerations Criteria
Myeloproliferative neoplasms (MPNs) are a group of heterogeneous disorders of the hematopoietic system that include myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). PV and ET are characterized by significant thrombohemorrhagic complications and a high risk of transformation to MF and acute myeloid leukemia. The diagnosis and management of PV and ET has evolved since the identification of mutations implicated in their pathogenesis. These NCCN Guideline Insights discuss the recommendations outlined in the NCCN Guidelines for the risk stratification, treatment, and special considerations for the management of PV and ET.
52
Efficacy and Safety of Low-Dose Aspirin in Polycythemia Vera
Raffaele Landolfi, Roberto Marchioli, Jack Kutti et al. · New England Journal of Medicine · 2004 · 1K citations · Full text